New drug combo shows promise for Hard-to-Treat stomach cancer
NCT ID NCT07559864
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs—regorafenib (a targeted therapy) and envafolimab (an immunotherapy)—can help people with advanced GIST that has a specific gene change (KIT exon 17 mutation) and has stopped responding to standard treatments. About 100 adults will be randomly assigned to receive either the combination or the doctor's choice of other treatments. The main goal is to see how long the cancer stays under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIST - GASTROINTESTINAL STROMAL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100101, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive GIST registry aims to unlock secrets of rare cancer
- New Two-Tooth clip aims to make stomach tumor removal safer and faster
- New hope for GIST: experimental combo targets hard-to-treat tumors
- New hope for advanced GIST: experimental drug NB003 takes on resistant tumors
- Scientists launch massive GIST registry to unlock secrets of rare cancer
- Real-World data on ripretinib for advanced GIST: what does it mean for patients?